Neuroprotection by XXXX in @entity19 models of permanent and transient focal cerebral ischemia.

@entity1 @entity4798 @entity64 @entity63 @entity19 @entity2500 @entity1092 @entity75 @entity51 @entity2052 @entity1188 @entity302
@entity1092 ( @entity2052 ) is a well-known anti- @entity302 and mood stabilizing drug. A growing number of reports demonstrate that @entity2052 is neuroprotective against various insults. Despite intensive efforts to develop new therapeutics for @entity64 over the past two decades, all treatments have thus far failed to show clinical effect because of treatment-limiting side effects of the drugs. Therefore, a safety-validated drug like @entity2052 would be an attractive candidate if it has neuroprotective effects against @entity63 insults. The present study was undertaken to examine whether pre- and post-insult treatments with @entity2052 protect against @entity4798 and @entity51 in @entity19 transient (tMCAO) and permanent @entity2500 (pMCAO) models. In the tMCAO (2 hr MCAO and 22 hr reperfusion) model, intraperitoneal injection of @entity2052 (300 mg/kg, i.p.) 30 min prior to MCAO significantly reduced the @entity1188 size and the @entity51 . @entity2052 treatment immediately after reperfusion significantly reduced the @entity1188 size. The administration of @entity2052 at 4 hr after reperfusion failed to reduce the @entity1188 size and the @entity51 . In the pMCAO model, treatment with @entity2052 (300 mg/kg, i.p.) 30 min prior to MCAO significantly attenuated the @entity1188 size, but did not affect the @entity51 . Western blot analysis of acetylated H3 and H4 protein levels in extracts from the @entity63 cortical area showed that treatment with @entity2052 increased the expression of acetylated H3 and H4 at 2 hrs after MCAO. These results demonstrated that treatment with @entity2052 prior to @entity63 attenuated @entity63 @entity75 in both @entity19 tMCAO and pMCAO models and treatment with @entity2052 immediately after reperfusion reduced the @entity1188 area in the tMCAO model. @entity2052 could therefore be evaluated for clinical use in @entity64 @entity1 .
